The FDA’s top drug regulator was placed on administrative leave after raising alarm about a secretive fast-track approval process that he claims bypasses decades of rigorous scientific oversight and centralizes dangerous power in one official’s hands.
Story Highlights
- Dr. George Tidmarsh, the FDA’s Center for Drug Evaluation and Research leader, was placed on administrative leave amid ethics allegations.
- Tidmarsh claims retaliation for opposing the new drug approval process that “circumvents rigorous scientific debate.”
- The new FDA system fast-tracks approvals for companies with “national health priorities” through tumor board-style reviews.
- Process allegedly gives chief medical officer Vinay Prasad control over “every drug approval.”
- Tidmarsh is considering resignation, calling the FDA environment “toxic” and “bad for the American people.”
Administrative Leave Follows Ethics Allegations
Dr. George Tidmarsh was placed on administrative leave after the Office of the General Counsel and Office of Inspector General received “serious concerns about his personal conduct,” according to HHS spokeswoman Emily Hilliard.
STAT News reported allegations that Tidmarsh used his regulatory authority to financially harm a former business associate. Tidmarsh denied these allegations in an ABC News interview, claiming the accusations represent retaliation for his criticism of controversial new FDA procedures.
The Food and Drug Administration’s top drug regulator has resigned after being accused of soliciting a bribe and tanking a company’s stock as part of an alleged revenge plot against a former colleague. https://t.co/tm2esMU5wu
— The Daily Beast (@thedailybeast) November 3, 2025
Concerns Over Fast-Track Drug Approval Process
Tidmarsh raised red flags about a new regulatory process designed to expedite drug reviews for “companies aligned with critical U.S. national health priorities.”
The system employs a tumor board-style review mechanism to fast-track approvals, departing from traditional FDA protocols. Tidmarsh warned this arrangement would be “different than the entire history of decades of the FDA,” expressing serious concerns about its legality and potential to undermine established safety standards that protect American patients.
Centralized Authority Raises Constitutional Questions
The new approval system allegedly concentrates unprecedented power in the FDA’s chief medical and scientific officer, Vinay Prasad, with Tidmarsh claiming it “puts Vinay Prasad in charge of every drug approval.”
This centralization of authority bypasses the rigorous scientific debate and peer review processes that have historically safeguarded drug approvals. Such concentration of regulatory power in a single official raises constitutional concerns about due process and checks and balances within federal agencies tasked with protecting public health.
Toxic Environment Threatens Public Safety
Despite HHS claims that Tidmarsh resigned, he told ABC News he was still considering his options while condemning the FDA’s current culture. “I would resign from a place as toxic as the current environment,” Tidmarsh stated, adding, “It’s toxic, it’s bad, it’s bad for the American people.”
His willingness to speak out despite facing serious allegations suggests deep institutional problems that could compromise the agency’s mission to ensure drug safety and effectiveness for American families.
